Quick Answer
Taysha Gene Therapies, Inc. reported Total Assets of $343.32 million for the year ending 2025.
- Taysha Gene Therapies, Inc. showed an increase of +114.1% in Total Assets from 2024 to 2025.
- This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $279.27 million | Q1 2021: $242.83 million | Q2 2021: $241.86 million | Q3 2021: $241.04 million | Q1 2022: $165.98 million | Q2 2022: $142.33 million | Q3 2022: $111.47 million | Q1 2023: $101.60 million | Q2 2023: $81.54 million | Q3 2023: $195.77 million | Q1 2024: $153.00 million | Q2 2024: $200.39 million | Q3 2024: $180.22 million | Q1 2025: $138.36 million | Q2 2025: $333.33 million | Q3 2025: $316.55 million.
- Over the full 7 years of available data (2019 to 2025), Taysha Gene Therapies, Inc.'s Total Assets has grown by 2,288,700.0%.
- Historical annual values: Fiscal year 2025: $343.32 million | Fiscal year 2024: $160.36 million | Fiscal year 2023: $172.73 million | Fiscal year 2022: $126.28 million | Fiscal year 2021: $213.96 million | Fiscal year 2020: $258.88 million | Fiscal year 2019: $15.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: